[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2020, Vol. 42 ›› Issue (9): 870-881.doi: 10.16288/j.yczz.20-189

• Review • Previous Articles     Next Articles

New molecular diagnostic technologies for clinical detection of SARS-CoV-2

Chunmei Xie1, Haiping Wu1, Xueping Ma1, Guohua Zhou1,2()   

  1. 1. Department of Clinical Pharmacy, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China
    2. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
  • Received:2020-06-22 Revised:2020-08-19 Online:2020-09-20 Published:2020-09-04
  • Contact: Zhou Guohua E-mail:ghzhou@nju.edu.cn
  • Supported by:
    Supported by the National Natural Science Foundation of China No(61871403);Jiangsu Provincial Science Fund for Distinguished Young Scholars No(BK20180005)

Abstract:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an ongoing pandemic of new coronavirus pneumonia (corona virus disease 2019, COVID-19). The virus has a long incubation period and strong infectivity, which poses a major threat to global health and safety. Detection of SARS-CoV-2 nucleic acid lies at the center of rapid detection of COVID-19, which is instrumental for mitigation of the ongoing pandemic. As of August 17, 2020, The National Medical Products Administration in China has approved 15 new coronavirus nucleic acid detection kits, 10 kits of which are based on reverse transcription-real-time quantitative PCR (RT-qPCR) technology. The remaining kits use five molecular diagnostic technologies different from RT-qPCR. This article reviews the principles, reaction time, advantages and disadvantages of above 15 detection kits, in order to provide references for rapid screening, diagnosis, prevention and control of COVID-19 and similar infectious diseases.

Key words: novel coronavirus, nucleic acid detection, molecular diagnostic technology